PURPOSE OF REVIEW
Liquid biopsy (LB) is rapidly transforming the management of hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (mBC). In this review, we discuss the most recent findings on circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), exploring their roles across the tre...
V. Frescura, M. Cristofanilli, C. Reduzzi et al.· Current Opinion in Oncology· 0 citations
A comprehensive overview of current knowledge on its applications in IBC is provided, highlighting the potential of circulating biomarkers to enhance disease characterization, diagnosis, risk assessment, and personalized treatment and the promising role of artificial intelligence in improving diagnostic accuracy.
E. Nicolò, M. Manai, Amr S. Soliman et al.· Critical reviews in oncology...· 1 citation
Evidence supporting ctDNA for early response monitoring during neoadjuvant therapy, postoperative minimal residual disease detection, and longitudinal molecular surveillance is summarized and ctDNA‐guided therapeutic interception strategies and emerging multimodal cell‐free DNA approaches are discussed.
S. Di Cosimo, V. Appierto, C. Reduzzi et al.· Cancer· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.